|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018213,
umls-concept:C0025644,
umls-concept:C0030705,
umls-concept:C0056978,
umls-concept:C0087111,
umls-concept:C0205177,
umls-concept:C0229671,
umls-concept:C0282553,
umls-concept:C0441889,
umls-concept:C0442805,
umls-concept:C1709059
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-1-24
|
|
pubmed:abstractText |
CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antithyroid Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CXCL10,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CXC,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Methimazole,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thyrotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Thyrotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Triiodothyronine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0300-0664
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
189-95
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16430719-Adult,
pubmed-meshheading:16430719-Antibodies,
pubmed-meshheading:16430719-Antithyroid Agents,
pubmed-meshheading:16430719-Chemokine CXCL10,
pubmed-meshheading:16430719-Chemokines, CXC,
pubmed-meshheading:16430719-Cross-Sectional Studies,
pubmed-meshheading:16430719-Female,
pubmed-meshheading:16430719-Goiter, Nodular,
pubmed-meshheading:16430719-Graves Disease,
pubmed-meshheading:16430719-Humans,
pubmed-meshheading:16430719-Interferon-gamma,
pubmed-meshheading:16430719-Male,
pubmed-meshheading:16430719-Methimazole,
pubmed-meshheading:16430719-Middle Aged,
pubmed-meshheading:16430719-Phenotype,
pubmed-meshheading:16430719-Receptors, Thyrotropin,
pubmed-meshheading:16430719-Thyroid Gland,
pubmed-meshheading:16430719-Thyroiditis, Autoimmune,
pubmed-meshheading:16430719-Thyrotropin,
pubmed-meshheading:16430719-Treatment Outcome,
pubmed-meshheading:16430719-Triiodothyronine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
|
|
pubmed:affiliation |
Metabolism Unit, Department of Medicine and CNR Institute of Clinical Physiology, University of Pisa School of Medicine, Pisa, Italy. a.antoinelli@med.unipi.it
|
|
pubmed:publicationType |
Journal Article
|
